#### UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

| OMB APPROVAL             |           |  |  |  |  |  |  |
|--------------------------|-----------|--|--|--|--|--|--|
| OMB Number:              | 3235-0287 |  |  |  |  |  |  |
| Estimated average burden |           |  |  |  |  |  |  |
| hours per response       | 0.5       |  |  |  |  |  |  |

longer subject to Section 16. Form 4 or Instruction 1(b).

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Form 5 obligations may Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| (Print or Type F   | Responses)  |                          |  |  |     |   |   |                        |                         |                                     |                           |                                  |  |   |              |                         |   |  |
|--|---|--------------------------|--|--|-----|---|---|------------------------|-------------------------|-------------------------------------|---------------------------|----------------------------------|--|---|--------------|-------------------------|---|--|
| Name and Address of Reporting Person*     Emerald Health Sciences Inc. |   |                          |  | 2. Issuer Name and Ticker or Trading Symbol<br>Nemus Bioscience, Inc. [NMUS] |     |   |   |                        |                         |                                     |                           | 5.                               | 5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  |   |              |                         |   |  |
| OFFICE 820<br>ST.  | 62, THE L   | (First)<br>ANDING, 200 - |  | 3. Date of 03/29/20  |     |   | Transaction   | (Mont                  | h/Day/                  | Year)                               |                           | -                                | Officer (give tit  | le below)   | Other (      | specify below           | )   |  |
| (Street)   |   |                          |  | 4. If Amendment, Date Original Filed(Month/Day/Year)                         |     |   |   |                        |                         |                                     |                           | _2                               | 6. Individual or Joint/Group Filing/Check Applicable Line) X_Form filed by One Reporting Person Form filed by More than One Reporting Person |   |              |                         |   |  |
| VANCOUV<br>(City)  | ER, AT V  | (State)                  | (Zip)  |  |     |   | Table I   | - Non-                 | Deriv                   | ative Secu                          | ırities                   |                                  |  |   |              |                         |   |  |
| 1.Title of Security (Instr. 3)  2. Transaction Date (Month/Day/Yo      |   |                          |  | 2A. Deemed<br>Execution Date, if<br>r) any<br>(Month/Day/Year                |     |   | 3. Transac  |                        |                         | curities Ac                         | Acquired (A) of (D)       |                                  | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)  |   | neficially 6 | 6.                      | 7. Nature<br>of Indirect<br>Beneficial<br>Ownership |  |
|  |   |                          |  | (Wionari   | Бау | r car j   | Code  | V                      |                         |                                     | (A) or<br>(D)             |                                  |  |   |              | r Indirect () (nstr. 4) | (Instr. 4)  |  |
| Common St  | ock   |                          | 03/29/2018   |  |     |   | С   |                        | 12,3                    | 35,000                              | A                         | \$<br>0.1                        | 53,116,250   |   |              | )                       |   |  |
| Common Stock 03/29/2018  |   |                          | 03/29/2018   |  |     |   | С   |                        | 20,0                    | 00,000                              | A                         | \$ 0.1                           | 73,116,250   |   | I            | )                       |   |  |
|  |   |                          | Table II   |  |     |   | ities Acqui   | this<br>curr<br>red, D | form<br>ently<br>ispose | are not i<br>valid ON<br>d of, or B | requir<br>IB co<br>enefic | ed to re<br>ntrol nu<br>ially Ow |  |   |              |                         | 1474 (9-02)   |  |
| 1. Title of<br>Derivative<br>Security<br>(Instr. 3)                    | 2. Conversion Date Or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Years) |                          | 3A. Deemed<br>Execution Date, it<br>any<br>(Month/Day/Year | 4. 5. N Transaction Deri Code Sect ar) (Instr. 8) Acq or D (D)               |     | warrants, o<br>umber of<br>vative<br>urities<br>uired (A)<br>isposed of<br>r. 3, 4, and | options, convertible secutes.  6. Date Exercisable and Expiration Date (Month/Day/Year) |                        |                         |                                     |                           | ecurities Derivative             |  | 10.<br>Ownershi<br>Form of<br>Derivativ<br>Security:<br>Direct (D<br>or Indirect<br>(I) | (Instr. 4)   |                         |   |  |
|  |   |                          |  | Code   | v   | (A)   | (D)   | Date<br>Exerc          | cisable                 | Expiration Date                     | On Tit                    | le                               | Amount or<br>Number of<br>Shares   |   | (Instr. 4)   | (Instr. 4)              |   |  |
| Series B<br>Convertible<br>Preferred<br>Stock                          | \$ 0.1  | 03/29/2018               |  | С  |     |   | 1,233.50  |                        | (1)                     | (1)                                 |                           | ommon<br>Stock                   | 12,335,000   | \$ 0  | 0            | D                       |   |  |
| Series F<br>Convertible<br>Preferred<br>Stock                          | \$ 0.1  | 03/29/2018               |  | С  |     |   | 2,000   | !                      | (2)                     | (2)                                 |                           | ommon<br>Stock                   | 20,000,000   | \$ 0  | 0            | D                       |   |  |

## **Reporting Owners**

|  | Relationships |              |         |       |  |  |  |
|--|---------------|--------------|---------|-------|--|--|--|
| Reporting Owner Name / Address   | Director      | 10%<br>Owner | Officer | Other |  |  |  |
| Emerald Health Sciences Inc.<br>OFFICE 8262, THE LANDING<br>200 - 375 WATER ST.<br>VANCOUVER, A1 V6B 0M9 |               | X            |         |       |  |  |  |

# **Signatures**

| James L. Heppell, Director      | 04/03/2018 |
|---------------------------------|------------|
| **Signature of Reporting Person | Date       |

## **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C.
- (1) The Series B Convertible Preferred Stock is convertible at any time, at the holder's election, and has no expiration date.
- (2) The Series F Convertible Preferred Stock is convertible at any time, at the holder's election, and has no expiration date.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.